FindMyKOL
Clinical trialNCT07843550Not, yet, recruitingPhase 1/2Interventional

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

NCT07843550 is a phase 1/2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is not yet recruiting. It studies Larotrectinib and Pembrolizumab in Solid Tumor. The registry lists an enrollment of 22 participants at 1 site in 1 country. The registry lists a start date of 1 Mar 2027 and a primary completion date of 13 Jul 2027. One of its registered investigators has a FindMyKOL profile.

SponsorM.D. Anderson Cancer CenterEnrollment22Solid Tumor
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07843550
FieldValue
Registry IDNCT07843550
StatusNot yet recruiting
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorM.D. Anderson Cancer Center
Enrollment22
Registered sites1
Countries1
ConditionsSolid Tumor
DrugsLarotrectinib and Pembrolizumab
Start1 Mar 2027
Primary completion13 Jul 2027
Study completion13 Jul 2029
Last update posted28 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07843550

Each answer restates registry values shown on this page.

What is NCT07843550?

NCT07843550 is a phase 1/2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Larotrectinib and Pembrolizumab in Solid Tumor.

Is NCT07843550 recruiting?

As of 21 Nov 2026, it is not yet recruiting.

Who leads NCT07843550?

The registry names David Hong, MD (principal investigator, UT MD Anderson) as the overall official.

Where does NCT07843550 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07843550 study?

The registered drug and biological interventions are Larotrectinib and Pembrolizumab.

When is NCT07843550 expected to complete?

The registry lists a primary completion date of 13 Jul 2027 and a study completion date of 13 Jul 2029. The sponsor last updated the record on 28 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.